NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

BCC - Basal Cell CarcinomaSCC - Squamous Cell CarcinomaMerkel Cell CarcinomaKeratoacanthoma of SkinMalignant Adnexal Tumors of the Skin (MATS)Tumors From Cutaneous T-cell Lymphoma (CTCL)Kaposi Sarcoma

Interventions

DRUG

L19IL2/L19TNF

Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks

Trial Locations (14)

20133

RECRUITING

Istituto Nazionale dei Tumori Fondazione IRCCS, Milan

28041

NOT_YET_RECRUITING

Hospital Universitario 12 de Octubre, Madrid

34125

RECRUITING

Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste

35128

NOT_YET_RECRUITING

Istituto Oncologico Veneto IOV, Padua

41009

RECRUITING

Hospital Universitario Virgen Macarena, Seville

44093

RECRUITING

CHU de Nantes - Hôpital Dieu, Nantes

53100

NOT_YET_RECRUITING

Azienda Ospedaliero Universitaria Senese Policlinico Le Scotte, Siena

80131

RECRUITING

"IRCCS Istituto Nazionale Tumori Fondazione Giovanni Pascale", Napoli

94800

RECRUITING

Institut Gustave Roussy, Villejuif

13 005

RECRUITING

Hôpital de la Timone, Marseille

Unknown

NOT_YET_RECRUITING

IRCCS Istituto Clinico Humanitas, Rozzano

00144

NOT_YET_RECRUITING

IFO- Istituto Dermatologico San Gallicano, Roma

00168

RECRUITING

Fondazione Policlinico Universitario A. Gemelli Università Cattolica del Sacro Cuore, Roma

08036

NOT_YET_RECRUITING

Hospital Clinic Barcelona, Barcelona

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY